Role of podocalyxin in astrocytoma: Clinicopathological and in vitro evidence

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1390-1396

  Huang, Tianxiang ^a   Jin, Xin ^b   He, Lei ^a   Zhang, Mingyu ^a   Wu, Jun ^a   Wang, Yanjin ^a   Fang, Jiasheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Akt; Astrocytoma; Cell survival; Disease free survival; Ki 67; Overall survival; Podocalyxin; Temozolomide

Indexed keywords

KI 67 ANTIGEN; PODOCALYXIN; PROTEIN KINASE B;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER STAGING; CELL VIABILITY; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

EID: 84884469173     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1556     Document Type: Article

References (15)

1. Lee SG, Kim K, Kegelman TP, et al: Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res 71: 6514-6523, 2011.
2. Starkweather AR, Sherwood P, Lyon DE, McCain NL, BovbjergDH and Broaddus WC: A biobehavioral perspective on depressive symptoms in patients with cerebral astrocytoma. JNeurosci Nurs 43: 17-28, 2011.
3. Nielsen JS and McNagny KM: The role of podocalyxin in health and disease. J Am Soc Nephrol 20: 1669-1676, 2009.
4. Riccioni R, Calzolari A, Biffoni M, et al: Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis 37: 218-225, 2006.
5. Yasuoka H, Tsujimoto M, Inagaki M, et al: Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma. J Clin Pathol 65: 399-402, 2012.
6. Larsson A, Johansson ME, Wangefjord S, et al: Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 105: 666-672, 2011.
7. Somasiri A, Nielsen JS, Makretsov N, et al: Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64: 5068-5073, 2004.
8. Sizemore S, Cicek M, Sizemore N, Peng, Ng KP and Casey G: Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67: 6183-6191, 2007.
9. Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, MatsutaniM, PriceJE and Kato Y: Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun 374: 394-398, 2008.
10. Kleihues P and Cavenne WK (eds): Pathology and Genetics of Tumours of the Nervous System. IARC press, Lyon, France, 2000.
11. Schilling H, Sehu KW and Lee WR: A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 38: 2081-2092, 1997.
12. Hopkin K, Edwards P, Harris A, Klausner R, Peters G, Selby P and StanleyM: Cancer. In: Molecular Biology of the Cell. Alberts B, Johnson A and Lewis J (eds). 4th edition. Garland Science, New York, NY, pp1324-1325, 2002.
13. Casey G, Neville PJ, Liu X, et al: Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 15: 735-741, 2006.
14. Khasraw M and Lassman AB: Advances in the treatment of malignant gliomas. Curr Oncol Rep 12: 26-33, 2010.
15. Borges KS, Castro-Gamero AM, Moreno DA, et al: Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol 138: 405-414, 2012.